Sg Americas Securities, LLC Savara Inc Transaction History

Sg Americas Securities, LLC

  • $30.5 Billion
  • Q1 2025

A detailed history of Sg Americas Securities, LLC transactions in Savara Inc stock. As of the latest transaction made, Sg Americas Securities, LLC holds 67,094 shares of SVRA stock, worth $204,636. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,094
Previous 51,589 30.05%
Holding current value
$204,636
Previous $158,000 17.72%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 15, 2025
BUY
$2.32 - $3.14 $35,971 - $48,685
15,505 Added 30.05%
67,094 $186,000
Q4 2024

Jan 17, 2025
BUY
$2.94 - $4.07 $18,610 - $25,763
6,330 Added 13.99%
51,589 $158,000
Q3 2024

Oct 03, 2024
BUY
$3.96 - $5.07 $179,225 - $229,463
45,259 New
45,259 $192,000
Q1 2024

May 06, 2024
SELL
$4.19 - $5.59 $67,647 - $90,250
-16,145 Reduced 32.38%
33,717 $168,000
Q4 2023

Jan 12, 2024
BUY
$3.18 - $4.9 $40,449 - $62,328
12,720 Added 34.25%
49,862 $234,000
Q3 2023

Oct 13, 2023
BUY
$2.97 - $3.88 $110,311 - $144,110
37,142 New
37,142 $140,000
Q1 2021

May 13, 2021
SELL
$1.17 - $2.33 $14,537 - $28,950
-12,425 Closed
0 $0
Q4 2020

Feb 04, 2021
BUY
$1.0 - $1.47 $2,117 - $3,111
2,117 Added 20.54%
12,425 $14,000
Q3 2020

Nov 09, 2020
SELL
$1.09 - $2.21 $16,368 - $33,187
-15,017 Reduced 59.3%
10,308 $11,000
Q2 2020

Jul 20, 2020
BUY
$1.8 - $3.05 $23,178 - $39,274
12,877 Added 103.45%
25,325 $63,000
Q1 2020

Apr 30, 2020
BUY
$1.91 - $4.08 $23,775 - $50,787
12,448 New
12,448 $26,000

Others Institutions Holding SVRA

# of Institutions
140
Shares Held
153M
Call Options Held
55.6K
Put Options Held
600
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $348M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email